Business, energy, technology, markets and global industry news from Business News Today

Pharma & Biotech

PharmaDeviceNews Pharma & Biotech
Representative image of a urologist discussing overactive bladder and benign prostatic hyperplasia treatment data with an older male patient, reflecting Sumitomo Pharma America’s AUA 2026 vibegron findings in men aged 75 and older.
Pharma & Biotech

Can vibegron strengthen Sumitomo Pharma America’s urology position after AUA 2026?

Older men with OAB and BPH remain hard to treat. Sumitomo Pharma America’s vibegron data may sharpen the next urology market test.

Read More
Representative image of a modern bioanalytical laboratory, highlighting how Thermo Fisher Scientific’s PPD Clinical Research expansion in Gothenburg strengthens biomarker testing and complex drug development support for pharmaceutical and biotechnology companies.
Pharma & Biotech

Why Thermo Fisher’s new Gothenburg lab matters for the next phase of complex drug development

Complex therapies need deeper trial data. Thermo Fisher’s Gothenburg lab shows why bioanalysis is becoming a CRO battleground.

Read More
Representative image: A home health clinician speaks with an elderly couple during an in-home care consultation, reflecting Enhabit’s move into private ownership under Kinderhook Industries as the home health and hospice sector faces rising demand, tighter margins, and renewed private equity interest.
Pharma & Biotech

Why Kinderhook’s Enhabit acquisition could reset the home health and hospice playbook

Home care demand is rising, but margins remain tight. Enhabit’s Kinderhook exit tests whether private equity can unlock scale without care risk.

Read More
Representative image: A clinical research laboratory setting illustrates Meiji Seika Pharma’s nacubactam Phase III progress, as the novel β-lactamase inhibitor advances the fight against complicated urinary tract infections, acute pyelonephritis and antimicrobial resistance.
Pharma & Biotech

Nacubactam trial win gives Meiji Seika Pharma a stronger AMR case, but approval hurdles remain

Antibiotic resistance needs new tools. Meiji Seika Pharma’s nacubactam now has Phase III data, but regulators must judge its real-world fit.

Read More
Representative image: Science-backed skincare research is moving closer to longevity science, as AV Laboratories highlights how IVF-inspired bioscience and regenerative medicine thinking could reshape the future of premium skin wellness.
Pharma & Biotech

Can IVF-inspired skincare move AVL beyond beauty marketing into longevity science?

Beauty wants biotech credibility. AVL’s IVF-inspired skincare push tests whether longevity science can reshape premium skincare.

Read More
Representative image: A clinician reviews bladder imaging during a urology consultation, reflecting Ferring Pharmaceuticals’ ADSTILADRIN re-induction data and the growing focus on bladder-sparing treatment strategies for BCG-unresponsive non-muscle invasive bladder cancer.
Pharma & Biotech

Can Ferring turn real-world ADSTILADRIN use into a broader NMIBC treatment strategy?

Bladder-sparing therapy needs better sequencing. Ferring’s ADSTILADRIN re-induction signal raises hope, but durability is the real test.

Read More
Pharma & Biotech

Is PMS relief becoming a consumer wellness category? Bayer’s Midol in Motion campaign suggests so

PMS relief is moving beyond pain pills. Bayer’s Midol campaign ties symptom care to movement, creators, and menstrual wellness.

Read More
Pharma & Biotech

Can Amylyx turn open-label AMX0035 signals into a credible Phase 3 Wolfram syndrome trial?

Amylyx has rare disease momentum, but open-label data are not destiny. AMX0035 now faces its real Wolfram syndrome test.

Read More
Representative image: A clinical researcher reviews liver cancer scan data in an oncology research setting, illustrating the growing focus on Agenus’ botensilimab and balstilimab combination in post-immunotherapy hepatocellular carcinoma treatment.
Pharma & Biotech

Can Agenus turn botensilimab and balstilimab into a serious post-ICI liver cancer contender?

Post-ICI liver cancer has few strong options. Agenus’ BOT plus BAL data raise the next question: can durability survive larger trials?

Read More
Pharma & Biotech

NUBEQA data at AUA 2026 sharpens Bayer’s mCSPC positioning against androgen receptor rivals

Bayer has stronger NUBEQA mCSPC data. The tougher test is whether clinicians view ARASEC as confirmatory or merely supportive.

Read More